Skip to main content

Table 1 Baseline characteristics and frequency of eight targetable genomic alterations of 3115 NSCLC patients from the DFCI cohort according to tumor histology

From: Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology

DFCI cohort Adenocarcinoma Squamous cell carcinoma Lung carcinoid Large cell carcinoma Adenosquamous carcinoma Othera Total
Age at diagnosis Median 66 68 58.5 64 67 65.5 66
Sex Male (%) 883 (36.9%) 204 (60.5%) 16 (22%) 10 (42%) 8 (53%) 135 (50%) 1256 (40.4%)
Female (%) 1512 (63.1%) 133 (39.5%) 58 (79%) 14 (58%) 7 (47%) 135 (50%) 1859 (59.6%)
Site Primary (%) 1400 (58.5%) 244 (72.4%) 62 (84%) 13 (54%) 14 (93%) 133 (49.3%) 1866 (59.9%)
Metastasis (%) 910 (38.0%) 77 (22.8%) 11 (15%) 11 (46%) 1 (7%) 111 (41.1%) 1121 (36.0%)
Local Recurrence (%) 36 (1.5%) 9 (2.7%) 0 (0%) 0 (0%) 0 (0%) 5 (1.9%) 48 (1.5%)
Unspecified (%) 49 (2.0%) 7 (2.1%) 1 (1%) 0 (0%) 0 (0%) 21 (7.8%) 80 (2.6%)
Smoking status Current (%) 375 (15.7%) 91 (27.0%) 3 (4%) 8 (33%) 2 (13%) 52 (19.3%) 531 (17.0%)
Former (%) 1420 (59.3%) 214 (63.5%) 36 (49%) 12 (50%) 11 (74%) 170 (63.0%) 1863 (59.8%)
Never (%) 600 (25.0%) 32 (9.4%) 35 (48%) 4 (16%) 2 (13%) 48 (17.8%) 721 (23.1%)
Targetable alterations EGFRL858R/exon19del/exon20ins (%) 429 (17.9%) 3 (0.9%) 0 (0%) 0 (0%) 3 (20%) 20 (7.4%) 455 (14.6%)
KRASG12C (%) 367 (15.3%) 7 (2.1%) 0 (0%) 3 (12%) 0 (0%) 28 (10.4%) 405 (13.0%)
MET amp/exon14skipping (%) 108 (4.5%) 5 (1.5%) 0 (0%) 1 (4%) 2 (13%) 12 (4.4%) 128 (4.1%)
BRAFV600E (%) 51 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (1.9%) 56 (1.8%)
ALK fusion (%) 61 (2.5%) 3 (0.9%) 0 (0%) 0 (0%) 0 (0%) 8 (3.0%) 72 (2.3%)
ROS1 fusion (%) 27 (1.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (1.5%) 31 (1%)
RET fusion (%) 35 (1.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (0.7%) 37 (1.2%)
NTRK fusion (%) 3 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.4%) 4 (0.1%)
Total N (% of total samples) 2395 (76.9%) 337 (10.8%) 74 (2.4%) 24 (0.8%) 15 (0.5%) 270 (8.6%) 3115
  1. a Includes non-small cell lung cancer not otherwise specified (NOS), pleomorphic carcinoma of the lung, neuroendocrine lung carcinoma NOS, sarcomatoid carcinoma of the lung, adenoid cystic carcinoma of the lung, giant cell carcinoma of the lung, spindle cell carcinoma of the lung, inflammatory myofibroblastic lung tumor, basaloid carcinoma of the lung, ciliated muconodular papillary tumor of the lung, and lymphoepithelioma-like carcinoma of the lung